AC Immune SA (NASDAQ:ACIU) Short Interest Down 14.6% in April

AC Immune SA (NASDAQ:ACIUGet Rating) was the recipient of a large decline in short interest during the month of April. As of April 30th, there was short interest totalling 233,800 shares, a decline of 14.6% from the April 15th total of 273,900 shares. Currently, 0.6% of the company’s stock are short sold. Based on an average daily volume of 100,900 shares, the days-to-cover ratio is currently 2.3 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. UBS Group AG boosted its stake in shares of AC Immune by 191.2% during the 2nd quarter. UBS Group AG now owns 54,825 shares of the company’s stock worth $198,000 after acquiring an additional 36,000 shares during the period. Susquehanna International Group LLP boosted its stake in AC Immune by 720.8% in the 4th quarter. Susquehanna International Group LLP now owns 59,916 shares of the company’s stock valued at $122,000 after purchasing an additional 52,616 shares during the period. Dimensional Fund Advisors LP bought a new stake in AC Immune in the 1st quarter valued at $108,000. Jane Street Group LLC bought a new stake in AC Immune in the 4th quarter valued at $87,000. Finally, Balyasny Asset Management LLC bought a new stake in AC Immune in the 3rd quarter valued at $82,000. 16.78% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ACIU has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of AC Immune in a research report on Wednesday, April 19th. lowered AC Immune from a “hold” rating to a “sell” rating in a research report on Monday, April 17th.

AC Immune Trading Down 0.9 %

Shares of NASDAQ ACIU opened at $2.09 on Monday. AC Immune has a 12 month low of $1.68 and a 12 month high of $3.90. The stock has a 50 day moving average of $2.18 and a 200-day moving average of $2.31. The company has a market capitalization of $174.62 million, a P/E ratio of -2.38 and a beta of 0.59.

About AC Immune

(Get Rating)

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.

Further Reading

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with's FREE daily email newsletter.